Biostem Technologies (BSEM) investor relations material

Company overview and business model

• Focuses on perinatal tissue-based therapies for advanced wound care and surgical applications, leveraging proprietary processing technologies to support tissue repair and regeneration.

• Expanded product portfolio through the acquisition of BioTissue’s surgical and wound care business, including Neox® and Clarix® product lines and a national sales infrastructure.

• Products are distributed through direct sales, independent agents, and distributors, with a diversified presence across physician offices, hospitals, and ambulatory surgical centers.

• Operates a vertically integrated, FDA-registered, AATB-accredited manufacturing facility, with plans to transition acquired products in-house to improve margins.

• Target patient populations include those with chronic wounds and post-surgical healing needs, with a strategy to expand into hospital and surgical settings.

Financial performance and metrics

• For the six months ended June 30, 2026, pro forma combined revenue was $15.5M, with a net loss of $17.0M; for the year ended December 31, 2025, pro forma combined revenue was $76.6M, with a net loss of $9.3M.

• Revenue declined sharply in 2026 due to CMS reimbursement changes, with physician office revenue dropping 93% year-over-year, partially offset by new hospital revenue from the BioTissue acquisition.

• Gross profit for the six months ended June 30, 2026 was $9.4M, down 66% from the prior year period.

• As of June 30, 2026, cash and cash equivalents were $7.0M, with an accumulated deficit of $39.0M and current liabilities exceeding current assets.

• The company’s auditor included a going concern warning due to recurring losses, negative cash flows, and upcoming payment obligations.

Use of proceeds and capital allocation

• May receive up to $40M in gross proceeds from sales of common stock to Roth Principal Investments under the committed equity facility.

• Proceeds are expected to be used for working capital and general corporate purposes, with management retaining broad discretion over allocation.

• A $10M contingent payment is due for the Catalyze product acquisition, with additional liquidity needed to meet this and other obligations.